LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Inicio・Lista de Acciones・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Cerrado

Sector Salud

48.73 -1.93

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

48.53

Máximo

48.76

Métricas clave
By Trading Economics
Ingresos	14B 1.7B
Ventas	300M 12B
P/B Media del Sector	14.05 103.001
BPA	2.07
Margen de beneficio	13.77
Empleados	34,100
EBITDA	13B 4.4B

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 meses	-1.24 downside

Dividendos
By Dow Jones
Próximas Ganancias	31 oct 2024
Fecha Próximo Dividendo	30 oct 2024
Próxima Fecha de Ex Dividendo	3 oct 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	101B
Apertura anterior	50.66
Cierre anterior	48.73

Noticias sobre sentimiento de mercado

By Acuity

37%

63%

77 / 365 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

48.11 / 49.92 Soporte y Resistencia

Bristol-Myers Squibb Co. Gráfico

Noticias Relacionadas

26 jul 2024, 14:08 UTC

Ganancias

Trending: Bristol Myers Squibb 2Q Adjusted EPS Beat Expectations

26 jul 2024, 11:54 UTC

Ganancias

Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales

25 abr 2024, 14:38 UTC

Ganancias

Trending: Bristol Myers Squibb Cuts '24 EPS Outlook, Plans Job Cuts in Cost Saving Efforts

25 abr 2024, 11:52 UTC

Ganancias

Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss

16 ago 2024, 11:30 UTC

Principales Noticias

The Feds Are 'Playing Nice' With Pharma, at Least for Now -- Heard on the Street -- WSJ

8 ago 2024, 10:30 UTC

Principales Noticias

Big Pharma Cuts R&D, Sending Shudders Through Industry -- Heard on the Street -- WSJ

29 jul 2024, 10:30 UTC

Principales Noticias

Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ

26 jul 2024, 14:51 UTC

Ganancias

Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win -- IBD

26 jul 2024, 13:53 UTC

Ganancias

Trending: Bristol Myers Squibb 2Q Adj EPS Beat Expectations

26 jul 2024, 11:28 UTC

Ganancias

Bristol Myers Stock Jumps. A Sales Jump for Eliquis Boosts Earnings. -- Barrons.com

26 jul 2024, 11:14 UTC

Ganancias

Bristol Myers Squibb Earnings Easily Beat On Cost Cuts; Stock Jumps -- IBD

26 jul 2024, 11:06 UTC

Ganancias

Bristol-Myers Squibb 2Q Adj Gross Margin 75.6% >BMY

26 jul 2024, 11:06 UTC

Ganancias

Bristol-Myers Squibb 2Q Gross Margin 73.2% >BMY

26 jul 2024, 11:04 UTC

Ganancias

Bristol-Myers Squibb Raises 2024 View To EPS 60c-EPS 90c Vs Prior Guidance 40c-70c >BMY

26 jul 2024, 11:04 UTC

Ganancias

Bristol-Myers Squibb Now Sees 2024 Total Rev Up Upper End of Low Single-Digit Range >BMY

26 jul 2024, 10:59 UTC

Ganancias

Bristol-Myers Squibb 2Q EPS 83c >BMY

26 jul 2024, 10:59 UTC

Ganancias

Bristol-Myers Squibb 2Q Net $1.68B >BMY

26 jul 2024, 10:59 UTC

Ganancias

Bristol-Myers Squibb 2Q Rev $12.2B >BMY

26 jul 2024, 10:59 UTC

Ganancias

Bristol-Myers Squibb 2Q Adj EPS $2.07 >BMY

19 jun 2024, 05:30 UTC

Principales Noticias

Adquisiciones, fusiones, absorciones

M&A Is Back. 4 Stocks That Could Be Targets. -- Barrons.com

28 may 2024, 22:51 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Bristol Myers Squibb Adds to Neurodegenerative Treatment Investments -- Market Talk

25 abr 2024, 12:36 UTC

Ganancias

Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts -- Barrons.com

25 abr 2024, 12:31 UTC

Adquisiciones, fusiones, absorciones

Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market -- IBD

25 abr 2024, 11:31 UTC

Ganancias

AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags -- IBD

25 abr 2024, 11:06 UTC

Ganancias

Bristol-Myers Squibb Still Sees 2024 Total Revenue Up Low-Single Digits >BMY

25 abr 2024, 11:05 UTC

Ganancias

Bristol-Myers Squibb Cuts 2024 View To EPS 40c-EPS 70c >BMY

25 abr 2024, 11:05 UTC

Ganancias

Bristol-Myers: Prioritizing Investing in Key Growth Brands, Optimizing Operations Across Organization >BMY

25 abr 2024, 11:04 UTC

Ganancias

Bristol-Myers: Focusing Resources on R&D Programs With Potential to Deliver Greatest Return on Investment >BMY

25 abr 2024, 11:04 UTC

Ganancias

Bristol-Myers: Executing Strategic Productivity Initiative Aimed at $1.5B Cost Savings by End 2025 >BMY

25 abr 2024, 11:03 UTC

Ganancias

Bristol-Myers Squibb 1Q Adjusted Gross Margin 75.5% >BMY

Comparación entre iguales

Cambio de precio

Bristol-Myers Squibb Co. Esperado

Precio Objetivo

By TipRanks

-1.24% caída

Estimación a 12 meses

Media 49.18 USD -1.24%

Máximo 62 USD

Mínimo 33.1 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Bristol-Myers Squibb Co. Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

13 ratings

Comprar

Mantener

Vender

De acuerdo con 13 analistas que ofrecen calificaciones bursátiles a para Bristol-Myers Squibb Co. Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

48.11 / 49.92Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bearish events outweigh bullish events.

Sentimiento

By Acuity

77 / 365 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.